Evidence map›Paper›PMID 34885135›Full record

ReviewCancers2021

Additional Value of PET Radiomic Features for the Initial Staging of Prostate Cancer: A Systematic Review from the Literature.

Priscilla Guglielmo, Francesca Marturano, Andrea Bettinelli, Michele Gregianin, Marta Paiusco, Laura Evangelista

Abstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Role of radiomic analysis of [European radiology · 2023
    Article
  14. Review
  15. Article
  16. Article
  17. The role of [European journal of nuclear medicine and molecular imaging · 2023
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Priscilla GuglielmoNuclear Medicine Unit, Veneto Institute of Oncology IOV-IRCCS, 31033 Castelfranco Veneto, Italy.ORCID 0000-0001-9150-4367
Francesca MarturanoMedical Physics Unit, Veneto Institute of Oncology IOV-IRCCS, 32168 Padova, Italy.ORCID 0000-0002-5430-1234
Andrea BettinelliMedical Physics Unit, Veneto Institute of Oncology IOV-IRCCS, 32168 Padova, Italy.ORCID 0000-0002-3539-3540
Michele GregianinNuclear Medicine Unit, Veneto Institute of Oncology IOV-IRCCS, 31033 Castelfranco Veneto, Italy.
Marta PaiuscoMedical Physics Unit, Veneto Institute of Oncology IOV-IRCCS, 32168 Padova, Italy.
Laura EvangelistaNuclear Medicine Unit, Department of Medicine DIMED, University of Padova, 32168 Padova, Italy.ORCID 0000-0002-5955-9488

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We performed a systematic review of the literature to provide an overview of the application of PET radiomics for the prediction of the initial staging of prostate cancer (PCa), and to discuss the additional value of radiomic features over clinical data. The most relevant databases and web sources were interrogated by using the query "prostate AND radiomic* AND PET". English-language original articles published before July 2021 were considered. A total of 28 studies were screened for eligibility and 6 of them met the inclusion criteria and were, therefore, included for further analysis. All studies were based on human patients. The average number of patients included in the studies was 72 (range 52-101), and the average number of high-order features calculated per study was 167 (range 50-480). The radiotracers used were [68Ga]Ga-PSMA-11 (in four out of six studies), [18F]DCFPyL (one out of six studies), and [11C]Choline (one out of six studies). Considering the imaging modality, three out of six studies used a PET/CT scanner and the other half a PET/MRI tomograph. Heterogeneous results were reported regarding radiomic methods (e.g., segmentation modality) and considered features. The studies reported several predictive markers including first-, second-, and high-order features, such as "kurtosis", "grey-level uniformity", and "HLL wavelet mean", respectively, as well as PET-based metabolic parameters. The strengths and weaknesses of PET radiomics in this setting of disease will be largely discussed and a critical analysis of the available data will be reported. In our review, radiomic analysis proved to add useful information for lesion detection and the prediction of tumor grading of prostatic lesions, even when they were missed at visual qualitative assessment due to their small size; furthermore, PET radiomics could play a synergistic role with the mpMRI radiomic features in lesion evaluation. The most common limitations of the studies were the small sample size, retrospective design, lack of validation on external datasets, and unavailability of univocal cut-off values for the selected radiomic features.

Indexed as

PETprostate cancerradiomicsstaging

Identifiers

PMID34885135
PMCPMC8657371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.